News
CRVO
1.460
+9.77%
0.130
CervoMed Inc. Presents 24-Week Interim Biomarker Data from Phase 2a Trial of Neflamapimod
NASDAQ · 4d ago
CervoMed Reports Interim Biomarker Data for Neflamapimod Trial
TipRanks · 4d ago
CervoMed Presents 24-Week Biomarker Data From Participants Enrolled In US Cohort Of Phase 2a Clinical Trial Of Neflamapimod, Oral P38α Inhibitor, In Nonfluent Variant Primary Progressive Aphasia, At CTAD Conference
Benzinga · 4d ago
Weekly Report: what happened at CRVO last week (1109-1113)?
Weekly Report · 4d ago
CervoMed: Buy Rating and $12 Price Target Maintained on Neflamapimod’s Broad Neurological Potential
TipRanks · 11/14 00:25
CervoMed Consensus Price Target Increased by 16.92% to $15.50
NASDAQ · 11/13 01:42
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 11/11 17:05
CervoMed price target lowered to $6 from $7 at Roth Capital
TipRanks · 11/10 16:29
CervoMed Inc. Reports Third Quarter 2026 Financial Results
NASDAQ · 11/10 00:02
CervoMed reports Q3 results
Seeking Alpha · 11/09 12:41
*CervoMed 2Q Research and Development Expenses About $3.7M >CRVO
Dow Jones · 11/09 12:31
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CervoMed (CRVO), Pyxis Oncology (PYXS) and Moderna (MRNA)
TipRanks · 11/09 12:01
Weekly Report: what happened at CRVO last week (1102-1106)?
Weekly Report · 11/09 09:44
Weekly Report: what happened at CRVO last week (1026-1030)?
Weekly Report · 11/02 09:44
CervoMed Inc. Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod
NASDAQ · 10/30 07:28
CervoMed Highlights New Neflamapimod Dementia Research Findings
TipRanks · 10/29 21:04
CervoMed announces publication of two articles supporting neflamapimod
TipRanks · 10/29 13:22
CervoMed’s Stroke Recovery Trial Nears Key Data Milestone for CRVO Investors
TipRanks · 10/28 16:30
Weekly Report: what happened at CRVO last week (1019-1023)?
Weekly Report · 10/26 09:44
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), CervoMed (CRVO)
TipRanks · 10/19 10:40
More
Webull provides a variety of real-time CRVO stock news. You can receive the latest news about CervoMed through multiple platforms. This information may help you make smarter investment decisions.
About CRVO
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.